Altimmune, Inc. (ALT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

8
ALT (Altimmune) Q2 2026: $519M Cash Fuels Late-Stage Liver Disease Franchise Expansion
August 12, 2026
7
Altimmune (ALT) Q1 2026: $535M Cash Runway Secured, Phase 3 MASH Launch Targets 2029 Readout
May 13, 2026
8
Altimmune (ALT) Q4 2025: $340M Cash Secured to Fund Phase III MASH Program Launch
March 05, 2026
8
Altimmune (ALT) Q3 2025: Cash Surges 60% as Pemvidutide Readies for Phase III Pivot
November 06, 2025
8
Altimmune (ALT) Q2 2025: $183M Cash Bolsters Phase 3 MASH Readiness Amid 59% Resolution Signal
August 12, 2025
10
Altimmune (ALT) Q1 2025: $100M Credit Facility Extends Runway as MASH Phase 2b Readout Nears
July 06, 2025
Altimmune (ALT) Q3 2024: $139M Cash Runway Extends Through 2026 as Phase 3 Obesity Program Secures FDA Alignment
November 12, 2024
Altimmune (ALT) Q2 2024: R&D Spend Rises 59% as Pembidutide Differentiation Narrative Intensifies
August 08, 2024
Altimmune (ALT) Q1 2024: R&D Spend Rises 25% as Phase 3 Obesity Program Readies for Expansion
May 09, 2024
Altimmune (ALT) Q4 2023: 74% Fat Loss Ratio, Differentiates Pembidutide in Obesity and MASH Pipeline
March 27, 2024
8
Altimmune (ALT) Q3 2023: R&D Spend Drops 9% as Obesity and NASH Programs Advance Toward Key Data
November 07, 2023
Altimmune (ALT) Q2 2023: 75% Liver Fat Reduction Highlights Differentiation in Obesity and NASH Pipeline
August 10, 2023
Altimmune (ALT) Q1 2023: $19M R&D Spend Accelerates Dual NASH and Obesity Pipeline, Partnership Now Prerequisite for Phase 3
May 11, 2023
Altimmune (ALT) Q4 2022: $75M R&D Commitment Drives Dual Obesity and NASH Pipeline Momentum
February 28, 2023

Browse all companies